Nalaganje...
HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researc...
Shranjeno v:
| izdano v: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7072136/ https://ncbi.nlm.nih.gov/pubmed/32013157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12020318 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|